公开(公告)号：US20220259210A1

公开(公告)日：2022-08-18

申请号：US17622579

申请日：2020-06-28

Applicant: SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.

Inventor： Qian WANG ,  Sijie SHU ,  Guangxin XIA ,  Hui GE ,  Bingbin ZHANG ,  Guoyong HUO ,  Lin ZHANG ,  Chen SHI ,  Jiangsong LOU ,  Chi ZHANG ,  Zhihui ZHANG ,  Yu MAO ,  Jianxin YU ,  Ying KE ,  Yanjun LIU

IPC: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00

Abstract: Disclosed are a pyrazolone-fused pyrimidine compound, a preparation method for same and applications thereof. Provided in the present invention is the pyrazolone-fused pyrimidine compound as represented by formula (II). The compound has improved inhibitory activity with respect to WEE1 kinase.

公开(公告)号：US20220324868A1

公开(公告)日：2022-10-13

申请号：US17623001

申请日：2020-08-28

Applicant: SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.

Inventor： Qian WANG ,  Guoyong HUO ,  Guangxin XIA ,  Jiangsong LOU ,  Sijie SHU ,  Hui GE ,  Lin ZHANG ,  Chen SHI ,  Zhihui ZHANG ,  Yu MAO ,  Bingbin ZHANG ,  Jianxin YU ,  Yanjun LIU ,  Ying KE ,  Chi ZHANG

IPC: C07D487/04

Abstract: Disclosed in the present invention are a pyrazolone-fused pyrimidine compound, and a preparation method and a use therefor. Provided in the present invention is a pyrazolone-fused pyrimidine compound as in formula (I), said compound having better inhibitory activity towards WEE1 kinase.